Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Short-duration versus 1-year adjuvant trastuzumab in early HER2 positive breast cancer: A meta-analysis of randomized controlled trials

Published:2019-05 Issue: Volume:75 Page:12-19
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Chen Lujia,Zhou Wenqi,Hu Xiaolei,Yi Man,Ye Changsheng,Yao Guangyu

Funder

Natural Science Foundation of Guangdong Province

Publisher

Elsevier BV

Subject

Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Reference44 articles.

1. Neoadjuvant therapy for HER2-positive breast cancer;Wuerstlein;Rev Recent Clin Trials,2017

2. Adjuvant trastuzumab in HER2-positive breast cancer;Slamon;New Engl J Med,2011

3. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccartgebhart;New Engl J Med,2005

4. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer;Romond;New Engl J Med,2005

5. Results of chemotherapy alone, with sequential or concurrent addition of 52 weeks of trastuzumab in the NCCTG N9831 HER2-positive adjuvant breast cancer trial;Perez;Cancer Res,2009

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic factor analysis and clinical significance of HER‑2‑positive breast cancers with negative lymph nodes and a tumor diameter ≤1 cm;Oncology Letters;2023-09-28

2. Appraisal of Systemic Treatment Strategies in Early HER2-Positive Breast Cancer—A Literature Review;Cancers;2023-08-30

3. Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics;Clinical Breast Cancer;2023-06

4. HER2+ Early Breast Cancer: From Escalation via Targeted and Post-Neoadjuvant Treatment to De-Escalation;Breast Care;2023

5. Trastuzumab treatment of invasive breast ductal carcinoma induces severe edema: a case report;Translational Cancer Research;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3